加载中
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
常规交易时段
US$5.44
+US$0.25 · +4.82%
盘中时间采用ET。市场数据可能有所延迟。
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
日内区间
当前US$5.44
52周区间
当前US$5.44
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
53
多空交织
风险
69
高风险
动量
39
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
日内区间
当前US$5.44
52周区间
当前US$5.44
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 3306 USD | 4134 USD | 1.18万 USD | 1.31万 USD |
| 毛利 | — | −3306 USD | −4134 USD | −1.18万 USD | −1.31万 USD |
| 研究与开发 | 977.19万 USD | 929.01万 USD | 1409.56万 USD | 930.01万 USD | 980.51万 USD |
| 销售、一般及管理费用 | 621.46万 USD | 560.85万 USD | 476.95万 USD | 562.12万 USD | 466.78万 USD |
| 营业费用 | 1598.66万 USD | 1489.86万 USD | 1886.1万 USD | 1492.12万 USD | 1447.28万 USD |
| 利息收入 | 15.38万 USD | 6.03万 USD | 2.77万 USD | — | 9.29 USD |
| 利息支出 | 1.52万 USD | 1.61万 USD | 1.38万 USD | 7027 USD | 9285 USD |
| 折旧和摊销 | 3918 USD | 3306 USD | 4134 USD | 1.18万 USD | 1.31万 USD |
| 营业利润 | −1598.66万 USD | −1490.19万 USD | −1886.51万 USD | −1493.3万 USD | −1448.59万 USD |
| 净利润 | −1585.06万 USD | −1485.78万 USD | −1885.12万 USD | −1527.41万 USD | −1449.52万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
